|
Nonsyndromic Deafness
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Mutations in the gene encoding KIAA1199 protein, an inner-ear protein expressed in Deiters' cells and the fibrocytes, as the cause of nonsyndromic hearing loss.
|
14577002 |
2003 |
|
Nonsyndromic Deafness
|
0.310 |
Biomarker
|
disease |
CLINGEN |
Mutations in the gene encoding KIAA1199 protein, an inner-ear protein expressed in Deiters' cells and the fibrocytes, as the cause of nonsyndromic hearing loss.
|
14577002 |
2003 |
|
Nonsyndromic Deafness
|
0.310 |
Biomarker
|
disease |
CLINGEN |
Distinct Expression Pattern of a Deafness Gene, KIAA1199, in a Primate Cochlea.
|
27403418 |
2016 |
|
Nonsyndromic Deafness
|
0.310 |
Biomarker
|
disease |
CLINGEN |
The localization of proteins encoded by CRYM, KIAA1199, UBA52, COL9A3, and COL9A1, genes highly expressed in the cochlea.
|
18448257 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Colorectal Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Furthermore, CEMIP silencing sensitized CRC cells to thapsigargin-induced apoptosis.
|
29024602 |
2018 |
|
Colorectal Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Collectively, KIAA1199 plays a critical role in maintaining an aggressive phenotype of tumor cells, and suppression of KIAA1199-related motilities of tumor cells contributes to reduced tumor metastasis in colorectal cancer.
|
28213952 |
2017 |
|
Colorectal Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
KIAA1199 was upregulated in CRC tissues, and was negatively regulated by miR-600.
|
29776371 |
2018 |
|
Colorectal Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Cell migration inducing hyaluronan binding protein (CEMIP) is a hyaluronic acid binding protein, the abnormal elevation of which is suggested as a contributor in the carcinogenesis of colorectal cancer (CRC).
|
29173982 |
2018 |
|
Colorectal Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Functional role of long non-coding RNA CASC19/miR-140-5p/CEMIP axis in colorectal cancer progression <i>in vitro</i>.
|
31011255 |
2019 |
|
Colorectal Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Collectively, our study reveals that KIAA1199 promotes metastasis of colorectal cancer cells via microtubule destabilization regulated by a PP2A/stathmin pathway, and suggests that KIAA1199 may be a promising target for preventing metastasis in colorectal cancer.
|
30202098 |
2019 |
|
Colorectal Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Targeting this node may provide a promising avenue for treatment of colon cancers that have acquired resistance to targeted therapies.<b>Significance:</b> MEK1 inhibitor-resistant colorectal cancer relies on the scaffold and endosomal protein CEMIP to maintain ERK1/2 signaling and Myc-driven transcription.<i></i>.
|
29915160 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.050 |
Biomarker
|
disease |
BEFREE |
Functional role of long non-coding RNA CASC19/miR-140-5p/CEMIP axis in colorectal cancer progression <i>in vitro</i>.
|
31011255 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.050 |
Biomarker
|
disease |
BEFREE |
Collectively, KIAA1199 plays a critical role in maintaining an aggressive phenotype of tumor cells, and suppression of KIAA1199-related motilities of tumor cells contributes to reduced tumor metastasis in colorectal cancer.
|
28213952 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
LncRNA TUG1 promoted KIAA1199 expression via miR-600 to accelerate cell metastasis and epithelial-mesenchymal transition in colorectal cancer.
|
29776371 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.050 |
Biomarker
|
disease |
BEFREE |
Collectively, our study reveals that KIAA1199 promotes metastasis of colorectal cancer cells via microtubule destabilization regulated by a PP2A/stathmin pathway, and suggests that KIAA1199 may be a promising target for preventing metastasis in colorectal cancer.
|
30202098 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.050 |
Biomarker
|
disease |
BEFREE |
Targeting this node may provide a promising avenue for treatment of colon cancers that have acquired resistance to targeted therapies.<b>Significance:</b> MEK1 inhibitor-resistant colorectal cancer relies on the scaffold and endosomal protein CEMIP to maintain ERK1/2 signaling and Myc-driven transcription.<i></i>.
|
29915160 |
2018 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our data suggest H3K27me3 loss as an important event in CEMIP mediated breast cancer carcinogenesis and progression.
|
31846842 |
2020 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
To gain deeper insights into the novel role of KIAA1199 in breast cancer, we modulated KIAA1199 expression using shRNA-mediated knockdown in two breast cancer cell lines (MDA-MB-231 and HS578T), expressing higher levels of KIAA1199.
|
24628760 |
2014 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, an immortal fibroblast cell line and two breast cancer cell lines expressed much lower amounts of KIAA1199 mRNA than their normal counterparts.
|
16157444 |
2006 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Involvement of DNA methylation in regulation of KIAA1199 expression was recapitulated in human breast cancer cell lines.
|
22970280 |
2012 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Involvement of DNA methylation in regulation of KIAA1199 expression was recapitulated in human breast cancer cell lines.
|
22970280 |
2012 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, an immortal fibroblast cell line and two breast cancer cell lines expressed much lower amounts of KIAA1199 mRNA than their normal counterparts.
|
16157444 |
2006 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our data suggest H3K27me3 loss as an important event in CEMIP mediated breast cancer carcinogenesis and progression.
|
31846842 |
2020 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
To gain deeper insights into the novel role of KIAA1199 in breast cancer, we modulated KIAA1199 expression using shRNA-mediated knockdown in two breast cancer cell lines (MDA-MB-231 and HS578T), expressing higher levels of KIAA1199.
|
24628760 |
2014 |